The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study
COMACHI 研究:帕妥珠单抗联合曲妥珠单抗和多西他赛作为一线疗法治疗日本不可手术或复发性 HER2 阳性乳腺癌患者的疗效和安全性
期刊:Breast Cancer Research and Treatment
影响因子:3
doi:10.1007/s10549-020-05921-x
Takahashi, Masato; Ohtani, Shoichiro; Nagai, Shigenori E; Takashima, Seiki; Yamaguchi, Miki; Tsuneizumi, Michiko; Komoike, Yoshifumi; Osako, Tomofumi; Ito, Yoshinori; Ikeda, Masahiko; Ishida, Kazushige; Nakayama, Takahiro; Takashima, Tsutomu; Asakawa, Takashi; Matsumoto, Sho; Shimizu, Daisuke; Masuda, Norikazu